Curis, Inc. reported fourth‑quarter 2025 results that included a net income of $19.4 million, or $1.23 per share, a turnaround from a $9.6 million loss in the same period a year earlier. The profit was largely the result of a $27.2 million one‑time, non‑cash gain from the sale of its former Erivedge partnership assets and the extinguishment of a royalty liability. Without that gain, the company would have posted a loss for the quarter.
Revenue for the quarter was $1.1 million, a sharp decline from $3.3 million in Q4 2024, reflecting the loss of recurring royalty income after the Erivedge sale on November 6 2025. The company’s operating expenses fell, driven by reductions in research and development and general and administrative costs, largely due to lower employee‑related and clinical costs.
In addition to the earnings announcement, Curis disclosed a private placement financing that will raise up to $80.8 million in gross proceeds. The deal includes three series of warrants exercisable at $0.75 per share and is expected to extend the company’s runway into the second half of 2027. The financing is a critical capital injection for a company that has been operating at a net loss and has a limited cash balance.
Management emphasized that the company’s future hinges on the development of its oncology candidate emavusertib. CEO James E. Dentzer said the company is “prioritizing NHL ahead of AML,” while CFO Diantha Duvall noted that “there will be no meaningful revenue” from the Erivedge wind‑down. The company also cautioned that it does not have sufficient cash on hand to support current operations for 12 months from the announcement date and will require substantial additional capital to advance emavusertib.
Market reaction to the results was muted, with investors focusing on the loss of recurring revenue and the ongoing liquidity challenges. Despite the positive net income, the company’s revenue miss and the need for further capital raised concerns about its long‑term viability. The PIPE proceeds provide a temporary reprieve, but the company remains in a precarious position as it seeks to secure additional funding to support its clinical program.
The earnings release and capital raise together represent a significant, material event that will influence investor perception and the company’s strategic trajectory. The one‑time gain masks underlying operational losses, and the loss of the Erivedge royalty stream leaves Curis with a narrow focus on emavusertib’s development and commercialization prospects. Investors will likely monitor the company’s ability to raise additional capital and the progress of its clinical trials as key indicators of future performance.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.